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Loss of succinate dehydrogenase activity results in
dependency on pyruvate carboxylation for cellular
anabolism
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The tricarboxylic acid (TCA) cycle is a central metabolic pathway responsible for supplying
reducing potential for oxidative phosphorylation and anabolic substrates for cell growth,
repair and proliferation. As such it thought to be essential for cell proliferation and tissue
homeostasis. However, since the initial report of an inactivating mutation in the TCA cycle
enzyme complex, succinate dehydrogenase (SDH) in paraganglioma (PGL), it has become
clear that some cells and tissues are not only able to survive with a truncated TCA cycle, but
that they are also able of supporting proliferative phenotype observed in tumours. Here, we
show that loss of SDH activity leads to changes in the metabolism of non-essential amino
acids. In particular, we demonstrate that pyruvate carboxylase is essential to re-supply the
depleted pool of aspartate in SDH-deﬁcient cells. Our results demonstrate that the loss of
SDH reduces the metabolic plasticity of cells, suggesting vulnerabilities that can be targeted
therapeutically.
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P
heochromocytoma (PCC) and paraganglioma (PGL) are
neuroendocrine tumours arising in the adrenal medulla and
in paraganglia of the autonomous nervous system,
respectively. Since the original discovery of SDHD mutations in
hereditary PGL in 2000, the genes encoding all four proteins that
constitute the succinate dehydrogenase (SDH) complex as well as
the required assembly factor (SDH assembly factor 2: SDHAF2)
have been shown as tumour-suppressor genes in familial and
apparently sporadic PCC and PGL1–5. Interestingly, SDHB
mutation carriers were speciﬁcally shown to be predisposed to
malignant6 and particularly aggressive forms of the disease7.
The effects of all these mutations are to abolish SDH activity,
which results in high steady-state intracellular concentrations of
succinate3,4,8–11.
A growing number of tricarboxylic acid (TCA) cycle
intermediates, namely succinate and fumarate, are now
considered oncometabolites, acting in part through the aberrant
activation of transcription factors and global epigenetic repro-
gramming11–13. Indeed, both SDH and fumarate hydratase-
mutant tumours have been shown to elicit a pseudohypoxic
phenotype through high steady-state levels of succinate and
fumarate, respectively11,14–16. Tumours arising from such
mutations demonstrate stabilization and activation of the
hypoxia-inducible transcription factors, HIF1 and 2, which have
been shown to elicit hypoxia-like alterations in metabolism, such
as increased lactate dehydrogenase A (LDHA) expression and
lactate production8,9,17,18. However, the direct metabolic
consequences of SDH loss are as yet uncharacterized. It was
recently shown that loss of another TCA cycle enzyme associated
with a hereditary cancer syndrome, fumarate hydratase, led to
signiﬁcant metabolic reprogramming of the mitochondria, which
was essential for continued cell viability18,19. Indeed, both genetic
and hypoxia-mediated disruption of the TCA cycle has been
suggested to result in alterations in cellular metabolic activity,
resulting in cells that are more reliant on reductive carboxylation
of glutamine for the provision of carbon for anabolic purposes
than oxidative TCA cycle metabolism20–22. These data suggested
that certain cell types are capable of re-wiring their metabolic
network in response to the loss of a fully functional TCA cycle,
but that despite this, the resulting metabolic phenotype is capable
of sustaining oncogenic transformation.
We therefore sought to investigate how cells deﬁcient in SDH
activity through deletion of the SDHB subunit maintain their
proliferation and viability. We found that in the absence of a fully
functional TCA cycle, cells become deﬁcient for a number of
key central carbon metabolites, such as citrate, malate and
aspartate. Aspartate synthesis is maintained through pyruvate
carboxylation, which SDH-deﬁcient cells become critically
dependent on for their proliferation and survival. Finally,
we found that, despite the use of reductive carboxylation to
metabolize glutamine, SDH-deﬁcient cells are unable to reverse
their deﬁciency.
Results
Amino-acid metabolism is perturbed in SDH-mutated tumours.
To explore predicted changes in tumourigenic metabolic path-
ways, we performed a bioinformatic analysis of the transcriptome
of 186 PCC/PGL (including 23 SDH-mutated tumours) using a
previously described subset of metabolic genes identiﬁed as being
important in tumorigenesis23. This unbiased analysis segregated
SDH-mutated from non-SDH-related tumours, suggesting that
they exhibit a distinct metabolic phenotype (Supplementary Fig. 1
and Supplementary Table 1a,b). Gene ontology analysis of
the differentially regulated pathways showed that the most
highly dysregulated metabolic pathways involved amino-acid
metabolism, with speciﬁc reference to the non-essential amino
acids alanine, aspartate and glutamate as the most affected
(Supplementary Table 1c,d). We performed an analysis of the
steady-state concentrations of these amino acids using the
previously characterized immortalized mouse chromafﬁn cell
(imCC) lines (wild-type; WT, Sdhb / ; clones 6 and 8) as a
model, which represent the cell type from which PCC arise in
patients. We found that all three amino acids identiﬁed from the
transcriptomic screen were signiﬁcantly altered in SDH-deﬁcient
cells, with aspartate concentrations particularly affected (Fig. 1a).
In addition, steady-state concentrations of glycine, proline and
serine were also altered, although the effect was not consistent
between the clones with respect to glycine and proline
(Supplementary Fig. 2a). To conﬁrm the physiological
signiﬁcance of alterations in the concentrations of alanine,
aspartate and glutamate, we performed a targeted analysis of
amino-acid concentrations in SDH-mutated human PCC/PGL
tumours compared with non-SDH mutated ones. Alongside
succinate, which was greatly elevated as expected in SDH-mutated
tumours, aspartate and the related amino acid, asparagine,
were both decreased (Fig. 1b). In addition, the change in serine
concentration was also recapitulated (Supplementary Fig. 2b).
Sdhb / cells exhibit altered pyruvate metabolism. Aspartate
production in most cells occurs mainly through oxidative TCA
cycle metabolism, which SDH-deﬁcient cells would be expected to
lack. We therefore investigated the steady-state concentrations
of TCA cycle intermediates, and observed, in addition to the
previously reported truncated TCA cycle (high succinate, low
fumarate and malate11,16), a signiﬁcantly reduced steady-state
citrate (Fig. 1c). Both reduced aspartate and citrate steady-state
concentrations suggest alterations in the metabolism of the
glycolytic metabolite, pyruvate, which also represents the
glycolytic entry point into the TCA cycle. We investigated this
phenomenon by incubating both the imCC cell model, and a
novel Sdhb / mouse adrenal ﬁbroblast (MAF) cell line model
(Supplementary Fig. 2c–e) with 13C-enriched glucose. Consistent
with the pseudohypoxic phenotype previously reported in
SDH-deﬁcient cells9,14, we noted increased lactate production
and excretion (Fig. 1d), along with the additional observation
of increased alanine synthesis and excretion (Supplementary
Fig. 3a).
Signiﬁcant synthesis of metabolites arising downstream from
pyruvate through the TCA cycle in both WT and Sdhb knockout
(KO) cells were also observed through the detection of label
incorporation from glucose into glutamate, succinate and
aspartate (Fig. 2a–c). The isotopomers of glutamate and aspartate
produced in the Sdhb WT and KO, however, were signiﬁcantly
different suggesting the implication of differential metabolic
pathways (Fig. 2a,c, and Supplementary Fig. 3b). Mitochondrial
pyruvate can either be oxidatively decarboxylated by pyruvate
dehydrogenase (PDH) to form acetyl coA, or carboxylated by PC
to form oxaloacetate (OAA). In WT cells, the 13C-[4,5]-glutamate
species was the major isotopomer observed from 13C-[1,2]-
glucose, consistent with the oxidative decarboxylation of pyruvate
by PDH (Fig. 2a,d, and Supplementary Fig. 3b). However, in Sdhb
KO cells, the relative contribution of the 13C-[4,5]-glutamate was
reduced by about 50%, and replaced by 13C-[2,3]-glutamate,
which represents incorporation of labelled OAA into the TCA
cycle (Fig. 2a,e and Supplementary Fig. 3b). This suggests that in
SDH-deﬁcient cells there is an increase in OAA synthesis and
metabolism through the activity of PC, which compensates for
the reduction in pyruvate oxidation by providing necessary
carbons for continued mitochondrial metabolism and cellular
anabolism. Transamination of OAA produces aspartate, the
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metabolism of which we show to be dysregulated in SDH-
deﬁcient cells and tumours (Fig. 1a,b). We therefore examined
13C incorporation from glucose into this amino acid, and found
that it conﬁrmed the switch in pyruvate oxidation to carboxyla-
tion in the Sdhb / cells. Indeed, although WT cells were
observed to synthesize 13C-[1,2]/[3,4]-aspartate through oxidative
TCA cycle activity, SDH-deﬁcient cells showed a signiﬁcant
induction of PC activity to synthesize 13C-[2,3]-aspartate from
mitochondrial OAA (Fig. 2c–e). Accordingly, expression of PC
was induced in both the imCC cell line model (Fig. 2f), and in
SDH-mutated tumours (Fig. 2g and Supplementary Table 2),
which may support increased ﬂux through this enzyme. As the
sole source of mitochondrial OAA in SDH-deﬁcient cells is
through the activity of PC, we hypothesized that this metabolite
may be limiting for the synthesis of citrate in SDH-deﬁcient cells,
resulting in the low steady-state citrate concentrations observed
(Fig. 1c). Owing to the naturally low levels of OAA, we assessed
steady-state concentrations using an enzymatic assay, and
observed reduced OAA concentrations in SDH-deﬁcient cells
(Fig. 2h). Importantly, when cells were treated with the speciﬁc
glutaminase inhibitor, Bis-2-(5-phenylacetamido-1,3,4-thiadia-
zol-2-yl)ethyl sulphide (BPTES), concentrations of OAA were
decreased only in the WT cells, showing as expected, that
SDH-deﬁcient cells do not metabolize glutamate produced by
glutaminase as a source of OAA. Interestingly, we noted
enrichment of isotope incorporation from glucose into acetate
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Figure 1 | TCA cycle dysfunction in SDH-deﬁcient cells. Loss of succinate dehydrogenase leads to perturbations in amino-acid metabolism,
TCA cycle dysfunction and aerobic glycolysis. (a) Abundance of alanine, aspartate and glutamate decrease in imCC Sdhb-null (KO c6 and c8) cells relative
to wild-type (WT) control, as assessed using GC–MS (n¼ 3). ****Po0.0001 as calculated by a Kruskal–Wallis test. (b) Steady-state succinate, aspartate
and asparagine in SDH-mutated patients’ tumours (n¼ 3) compared with non-SDH mutated tumours (n¼ 3). As expected, succinate is signiﬁcantly
increased, whereas aspartate and asparagine are decreased. (c) Abundance of succinate, fumarate, malate and citrate are signiﬁcantly altered in Sdhb-KO
imCC (c6 and c8) cells relative to WTcontrol, as assessed using GC–MS (n¼ 3). ****Po0.0001 as calculated by a Kruskal–Wallis test. (d) SDH-deﬁcient
cells exhibit aerobic glycolysis as shown by increase lactate production from glucose. After 24 h of incubation with medium containing 13C-[1,2]-glucose,
the media were extracted and the abundance of different mass isotopomers of lactate excreted were quantiﬁed using NMR spectroscopy. 13C atoms
(arising from glucose) are shown as ﬁlled circles, whereas 12C atoms are empty circles (n¼ 3). All error bars shown represent s.d.
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in both cells and media, a ketone body product of acetyl-coA in
SDH-deﬁcient cells (Supplementary Fig. 3d,e), suggesting that
Sdhb-deﬁcient cells and perhaps tumours may exhibit a ketogenic
phenotype.
Aspartate synthesis is PC-dependent in Sdhb / cells. The
increased reliance of SDH-deﬁcient cells on PC activity for
aspartate synthesis, and the central role of aspartate in cellular
anabolism suggested that loss of PC activity would be incompa-
tible with cell growth and proliferation. We therefore tested
whether SDH-deﬁcient cells were dependent on PC activity by
knocking down its expression in the imCC cell model using two
independent short interfering RNA (siRNA) sequences (Fig. 3a
and Supplementary Fig. 4a). PC deﬁciency resulted in little effect
on cell number in WT cells, but resulted in complete ablation of
proliferation in SDH-deﬁcient cells (Fig. 3b and Supplementary
Fig. 4b). This, hence, conﬁrmed the essential role of PC in
SDH-deﬁcient cell growth and survival.
To be available for cytosolic biosynthetic processes, aspartate
produced in the mitochondria is exported across the mitochon-
drial inner membrane against a gradient of glutamate using an
aspartate-glutamate antiporter. Although expression of neither
of the two antiporters, SLC25A12 and 13, was increased in
SDH-deﬁcient cells (Fig. 3c and Supplementary 4c and d), protein
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in SDH-deﬁcient cells. MID, mass isotopomer distribution KO, Sdhb knockout.
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expression of SLC25A13 was noted as signiﬁcantly upregulated in
SDH-deﬁcient tumours (Fig. 3d and Supplementary Table 2).
This supported the model in which SDH-deﬁcient cells may be
more dependent on the production of aspartate from PC-derived
OAA in the mitochondria, and may therefore require increased
activity of the appropriate transporters to export it for
biosynthetic metabolism in the cytosol. As our cell line models
were grown in DMEM, which lacks aspartate, the cells are entirely
reliant on endogenous synthesis of aspartate for their growth and
proliferation. We hypothesized that, if available, SDH-deﬁcient
cells would take up more exogenous aspartate than their WT
counterparts. We therefore supplemented both WT and KO cells
with exogenous 13C4-aspartate and found that cells lacking SDH
activity demonstrated increased uptake and metabolism of this
amino acid (Fig. 3e,f and Supplementary Fig. 4e).
SDH-deﬁciency elicits reductive carboxylation of glutamine.
Having shown that SDH-deﬁcient cells display signiﬁcantly
increased synthesis of aspartate from glucose using PC activity,
and that they uptake more exogenous aspartate, we sought to
investigate whether glutamine metabolism was able to at least
partially compensate for the putative deﬁciency in cytosolic
aspartate. Glutamine is not only an amino acid, but also a major
source of carbon, the availability of which is essential for de novo
nucleotide biosynthesis and important for the synthesis of almost
all non-essential amino acids. We incubated both WT and
Sdhb-deﬁcient imCCs with 13C5-glutamine and the resulting
polar extracts of cells and media were analysed for the
incorporation of 13C into metabolites. Sdhb KO cells were found
to incorporate signiﬁcantly more glutamine carbon into succinate
than their WT counterparts (Fig. 4a), suggesting enhanced ﬂux of
glutamine carbons into the TCA cycle compared with glucose.
This ﬂux of glutamine carbons into the mitochondria could be
used to support export of aspartate synthesized through PC
activity in order to support cellular anabolism through the
aspartate/glutamate antiporter (SLC25A12 and 13).
Carbon from glutamine was signiﬁcantly enriched in both
aspartate and malate in positions consistent with oxidative TCA
cycle activity in WT imCC (13C4, 13C-[1,2] and 13C-[3,4]-malate
and aspartate; Fig. 4b–d). As expected, SDH-deﬁcient cells
produced neither isotopomers of these metabolites because of
their truncated TCA cycle (Fig. 4b,c,f). 13C-[1,2,3]/[2,3,4]-malate
and aspartate isotopomers were also noted in WT cells, but not in
Sdhb KO clones (Fig. 4b,c). These isotopomers are likely products
of the reductive carboxylation of glutamine—an observation
that is supported by the isotopomers of lactate identiﬁed in the
same samples, which can be produced through the activity of
malic enzyme or phosphoenolpyruvate carboxykinase, both of
which have been previously reported in tumours20,24,25 (Fig. 4e
and Supplementary Fig. 4f). Interestingly, although label
incorporation was observed in neither malate nor aspartate in
SDH-deﬁcient cells, evidence of reductive carboxylation of
glutamine could be observed from the only isotopomer of
lactate identiﬁed in these cells and in the media (13C-[2,3],
Fig. 4e,f and Supplementary Fig. 4f). This suggests that, in
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common with other systems in which the oxidative TCA cycle is
perturbed, there may be an increased reliance on reductive
carboxylation for the supply of carbons to metabolic
intermediates to support cellular anabolism20–22. This is likely
to be supported by the concerted, supportive transcriptional
response observed (Fig. 4g). In case the absence of observable
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Figure 4 | Sdhb / cells exhibit dysfunctional glutamate metabolism leading to reductive carboxylation. Glutaminolysis leads to incorporation of
13C5-glutamine into (a) succinate, (b) aspartate and (c) malate in wild-type cells. (a) A signiﬁcantly greater proportion of the succinate pool in Sdhb
 /
cells directly arises from glutamine incorporation into proximal TCA cycle metabolites (**P¼0.0036, Kruskall–Wallis performed on fully labelled values).
However, no isotopomers of aspartate (b) or malate (c) were observed in Sdhb / cells. (d) Diagrammatic representation of the oxidative (red) and
reductive (blue) metabolism of SDH wild-type cells. (e) Mass isotopomers of lactate after incubation of cells with 13C5-glutamine suggest incorporation of
carbons into lactate from reductive metabolism in SDH-deﬁcient cells. As the 13C-[1,2]-lactate and 13C-[2,3]-lactate isotopologues are made in equal ratios
through the action of oxidative TCA cycle metabolism in wild-type cells, the 13C-[2,3]-lactate isotopomer in these cells is an over-estimation of reductive
carbon incorporation. (f) Diagrammatic representation of the oxidative (red) and reductive (blue) metabolism of Sdhb / cells. (g) The enzymes involved
in the reductive metabolism of glutamine are differentially expressed in SDH-deﬁcient cells. Of interest, most enzymes with cytosolic reductive activity are
upregulated, whereas most with mitochondrial-localized reductive activity are downregulated. (h) Mass isotopomer distribution (MID) of intracellular
fumarate after cells were incubated for 48 h with 13C5-glutamine as measured using GC–MS. SDH-deﬁcient cells show decreased isotopomers produced
through oxidative metabolism (for example, mþ 1, mþ 2 and mþ4), whereas instead showing increased 13C incorporation through reductive metabolism
(mþ 3; P¼0.05, Kruskal–Wallis test on mþ 3 isotopomer values only). Abbreviations in metabolic diagrams: aKG, alpha-ketoglutarate; Ac, acetate;
AcCoA, acetyl coenzyme A; Ala, alanine; Asp, aspartate; Cit, citrate; Fum, fumarate; Gln, glutamine; Glu, glutamate; IC, isocitrate; Lac, lactate; Mal, malate;
OAA, oxaloacetate; Pro, proline; Pyr, pyruvate; Suc, succinate. KO, Sdhb knockout. For all metabolic data (a,b,c,e and h), n¼ 3 and error bars are s.d.
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label incorporation into aspartate and malate in the KO cells was
due to the sensitivity of our nuclear magnetic resonance (NMR)
spectroscopy approach, we also used a longer incubation time
(72 h) to analyse incorporation of glutamine carbons into these
metabolites, and used gas chromatography-mass spectrometry
(GC–MS) to analyse the resulting extracts. These data conﬁrmed
our previous analysis (Supplementary Fig. 4g–h), and in addition
we observed increased proportions of the mþ 3 isotopomer of
fumarate, consistent with reductive carboxylation (Fig. 4h).
However, the very low steady-state concentration of malate and
aspartate found in these cells (Fig. 1a,c) did not allow for
quantiﬁcation 13C incorporation from glutamine. This suggests
that although these two metabolites are produced from
glutamine, their metabolism is rapid enough to retain very low
steady-state concentrations in SDH-deﬁcient cells.
Discussion
Metabolic reprogramming has been proposed to be a core
hallmark of cancer26. As a central metabolic hub, it is likely that
some aspect of mitochondrial metabolic reprogramming exists
in most tumours27. Originating from a defect in a
central mitochondrial enzyme complex, SDH-mutated tumours
constitute an ideal genetic model for deciphering how metabolic
adaptation fuels cell growth and proliferation. It has long been
known that SDH-deﬁcient PCC/PGL demonstrate an altered
metabolic phenotype: not only through the inactivation of SDH
mitochondria function per se, but also via a pseudohypoxic
phenotype mediated by the effect of succinate accumulation on
the cellular transcriptome11,12,16. However, the details of the
direct effects of metabolic transformation due to loss of SDH
activity were as yet uncharacterized. Our transcriptomic and
metabolic tracer studies demonstrate that amino-acid metabolism
is altered in SDH-deﬁcient cells as a result of re-wiring of
mitochondrial metabolic pathways. We demonstrate that SDH-
deﬁcient cells increase PC-dependent carboxylation of pyruvate
to synthesize OAA in order to produce aspartate as well as
continue a truncated oxidative TCA cycle in the mitochondria. In
addition, SDH-deﬁcient cells are highly dependent upon
mitochondrial aspartate production from OAA, as disruption of
synthesis resulted in complete ablation of proliferation and a loss
of viability. Aspartate constitutes a key metabolic hub in the cell,
being a major precursor for protein and nucleotide biosynthesis,
as well as critical for the synthesis of other ‘non-essential’ amino
acids such as arginine and asparagine. With limited means of
producing aspartate in SDH-deﬁcient cells, the signiﬁcant
number of metabolic pathways that depend on it are likely to
be unable to cope with a decline in supply, as demonstrated here.
This loss of metabolic plasticity means that changes in the rate of
synthesis of aspartate is likely to determine the anabolic and
proliferative state of the cell. Finally, we show that glutamine and
glutamate are used to provide metabolic intermediates that are
lacking because of the truncation of the TCA cycle, but that the
ﬂux appears to be insufﬁcient to fully compensate for the lack of
oxidative TCA cycle activity. Altogether, our data indicate a
signiﬁcant loss of metabolic plasticity in SDH-deﬁcient cells, and
suggest novel therapeutic targets that would speciﬁcally disrupt
the metabolism of these tumours.
Methods
Tumour samples. Tumours were collected prospectively by the French ‘Cortico et
Me´dullosurre´nale: les Tumeurs Endocrines’ network. Ethical approval for the study
was obtained from the institutional review board (Comite´ de Protection des
Personnes Ile de France III, June 2012). Written informed consent for the sample
collection and subsequent analyses was obtained from all patients. The procedures
used for PCC/PGL diagnosis were in accordance with both internal and
international clinical practice guidelines28,29. Diagnosis was conﬁrmed by histology
in every case. A total of 202 consecutive cases of PCC/PGL, recruited over 15 years
(1993–2008), were included in this study. Fresh tumour samples collected during
surgery were immediately frozen and stored in liquid nitrogen until processing.
Formalin-ﬁxed parafﬁn-embedded tissues were used for immunohistochemical
analyses.
Generation of MAF cell lines. Primary MAF cell cultures were obtained from
entire adrenal glands of 6-week-old Sdhblox/lox mice12. Brieﬂy, glands were
dissected and placed into Ca2þ -and Mg2þ -free Locke’s buffer (154mM NaCl,
2.6mM KCl, 2.2mM K2HPO4, 0.95mM KH2PO4, 10mM glucose). Glands were
digested 30min in digestion buffer (glutamate- and pyruvate-free DMEM, 5.5mM
cysteine-HCl, 1mM CaCl2, 0.5mM EDTA) containing 0.22-mm-ﬁltered papain
(40Uml 1; Worthington) at 37 C and cells placed in culture. Sdhb knockout was
achieved after infection with 107 PFUml 1 of an adenovirus expressing Cre-
recombinase (Ad5CMV-Cre, CellBioLabs). All studies were performed in
accordance with the relevant guidelines of the French Ministry of Agriculture
(Authorization Executive Order A751532) for scientiﬁc experimentation on
animals, European Communities Council Directive and international ethical
standards. Cells were infected with 107 PFUml 1 of an adenovirus expressing
Cre-recombinase (Ad5CMV-Cre, CellBioLabs). A clonal approach by limiting
dilution cloning assay was used to obtain homogenous Sdhb / (KO) and
Sdhblox/lox (referred to as WT) MAF clones.
Cell culture. ImCC12 and MAF were cultured in DMEM, high glucose, GlutaMAX
supplement, pyruvate medium (GIBCO) supplemented with 10% fetal bovine
serum (GIBCO) and maintained in a humidiﬁed 5% CO2 atmosphere at 37 C.
Mycoplasma contamination was ruled out using the PCR Mycoplasma Test kit I/C
(PromKine, PK-CA91-1048).
Gene expression data. Gene expression proﬁles of human tumours were available
from a previous study, in which 186 PCC/PGL were analysed30. All the samples
were genotyped for the presence or the absence of germline and somatic mutations
in well-known PCC/PGL susceptibility genes. In total, there are 23 SDHx, 38 VHL,
30 NF1, 14 RET, 1 TMEM127, 3 MAX, 6 HRAS, 3 MET, 65 sporadic, 1 NF1/MET,
1 RET/HRAS and 1 TP53/CDKN2A/MET31. HG-U133 Plus 2.0 Affymetrix
GeneChip data from this previous study are available online as ArrayExpress
entry E-MTAB-733 (http://www.ebi.ac.uk/arrayexpress/).
Gene expression proﬁles of WT and Sdhb / MAF, imCC c6 and imCC c8
were assessed in duplicates using the GeneChip Mouse Gene 1.0 ST Array. Data are
available as ArrayExpress entry E-MTAB-3403.
13C-glucose, 13C-aspartate and 13C-glutamine labelling. Cells (6 106) were
plated onto two 15-cm dishes and cultured in standard medium for 24 h. Cells
were washed in PBS and the medium was then replaced by either fresh DMEM
(no glucose) with 1mM sodium pyruvate and 10mM 13C2-[1,2]-D-glucose (Sigma)
or DMEM (high glucose with pyruvate, no glutamine) supplemented with 2mM
13C5-L-glutamine (Sigma) for 24 h. For aspartate labelling, cells were cultured in
standard medium supplemented with 0.1mM 13C4-L-aspartate for 48 h.
Extraction of polar metabolites and NMR spectroscopy. Cells were washed with
ice-cold PBS and scraped in a pre-cooled acetonitrile/methanol/water (55:35:10)
solution. The cell lysates were vortexed for 15min at 4 C and immediately
centrifuged at 15,000g for 15min at 0 C. The supernatants were ﬁnally evaporated
using a SpeedVac concentrator and stored at  80 C until further analyses. For the
metabolomic extraction of conditioned media, 600 ml of an acetonitrile/methanol
(60:40) solution was added to 200 ml of cell media, and then processed as described
above. Dried NMR samples were resuspended in 60 ml of 100mM sodium
phosphate buffer containing 500mM TMSP ((3-trimethylsilyl)propionic-(2,2,3,3-d4)-
acid sodium salt) and 10% D2O, pH 7.0. Samples were vortexed, sonicated
(5–15min) and centrifuged brieﬂy (x2), before transferred to 1.7mm NMR tubes
using an automatic Gilson. Extraction was performed on three different cultures for
each labelling experiments.
One-dimensional (1D)-1H-NMR spectra and two-dimensional
(2D)-1H,13C-Heteronuclear Single Quantum Coherence Spectroscopy (HSQC)
NMR spectra were acquired using a 600-MHz Bruker Avance III spectrometer
(Bruker Biospin) with a TCI 1.7mm z-PFG cryogenic probe at 300 K. Spectral
widths were set to 7,812.5 and 24,155Hz for the 1H and 13C dimensions,
respectively. 16,384 complex data points were acquired for the 1D-spectra and 512
complex data points were acquired for the 1H dimension of 2D-1H,13C-HSQC
NMR spectra. An exponentially weighted non-uniform sampling scheme was used
for the indirect dimension. Here, 30% of 8,192 complex data points (2,458) were
acquired. 128 transients were recorded for the 1D-NMR spectra with a relaxation
delay of 4 s, and two transients were recorded for the 2D-1H,13C-HSQC NMR
spectra with a relaxation delay of 1.5 s. Each sample was automatically tuned,
matched and then shimmed (1D-TopShim) to a TMSP line width ofo2Hz before
acquisition of the ﬁrst spectrum. Total experiment time was B15min per sample
for 1D-1H-NMR spectra and 4.5 h per sample for 2D-1H,13C-HSQC NMR spectra.
1D-1H-NMR spectra were processed using the MATLAB-based MetaboLab
software32. All 1D data sets were zero-ﬁlled to 131,072 data points before Fourier
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9784 ARTICLE
NATURE COMMUNICATIONS | 6:8784 | DOI: 10.1038/ncomms9784 |www.nature.com/naturecommunications 7
& 2015 Macmillan Publishers Limited. All rights reserved.
Transformation. The chemical shift was calibrated by referencing the TMSP signal
to 0 p.p.m. 1D-spectra were manually phase corrected. Baseline correction was
achieved using a spline function32. 1D-1H-NMR spectra were exported into Bruker
format for metabolite identiﬁcation and concentration determination using
Chenomx 7.0 (ChenomxINC). 2D-1H,13C-HSQC NMR spectra were reconstructed
using compressed sensing in the MDDNMR and NMRpipe software33–35. The ﬁnal
spectrum size was 1,024 real data points for the 1H dimension and 16,384 real data
points for the 13C dimension. Analysis was performed using MetaboLab and
pyGamma software was used in multiplet simulations36. The methyl group of
lactate was used to calibrate the chemical shift based on its assignment in the
human metabolome database37.
Metabolite extraction and GC–MS analysis. Cells were seeded onto six-well
plates and cultured in standard medium for 24 h. Media was then replaced by
DMEM (high glucose with pyruvate, no glutamine) supplemented with 2mM
13C5-L-glutamine (Sigma) for 72 h. At the conclusion of tracer experiments, culture
media were aspirated and cells were washed twice with 0.9% NaCl saline solution.
Methanol ( 80 C) and water, containing 1 mg per well norvaline as internal
standard (4 C), were immediately added to each well and cells were scraped and
transferred to tube. Chloroform ( 20 C) was added to each tube followed by
vortex and separation into polar and nonpolar fractions by centrifugation. The
polar fractions were transferred to new tubes and evaporated to dryness by
SpeedVac concentration.
Derivatization of polar metabolites has been previously described20,38.
Brieﬂy, polar metabolites were derivatized to form methoxine-TBDMS
derivatives by incubation with 2% methoxylamine hydrochloride dissolved in
pyridine at 37 C for 1 h followed by addition of N-tert-butyldimethylsilyl-N-
methyltriﬂuoroacetamide with 1% tert-butyldimethylchlorosilane incubated at
37 C for 30–60min. Derivatized polar samples were analysed by GC–MS using a
DB-35MS column (30m 0.25mm i.d.  0.25 mm) installed in an Agilent 7890B
GC interfaced with an Agilent 5977A MS. Mass isotopomer distributions were
determined by integrating metabolite ion fragments and corrected for natural
abundance as previously described39.
Metabolite ion counts were normalized to norvaline and isoleucine ion counts
to normalize for varying derivatization efﬁciency and cell number, respectively.
siRNA experiments. A total of 50,000 cells were plated onto 12-well plates in
standard culture conditions. Twenty-four hours later, they were transfected with
150 ng of Silencer Select Pre-designed siRNA against PC (siRNA references s71354
and s71355; Life Technologies) or Silencer Select negative control using RNAiMax
reagent (Life Technologies) as described by the manufacturer. Forty-eight hours post
transfection, cells were passaged and efﬁciency of gene extinction was evaluated by
immunoﬂuorescence and reverse transcription–quantitative PCR (qPCR). Passaged
cells were retransfected 24h later to maintain long-term extinction.
Reverse transcription–qPCR. RNA extractions were performed with the
miRNeasy kit (Qiagen). A total of 500 ng RNA per sample was used for reverse
transcriptions using the RT reactions iScript cDNA Synthesis Kit (Bio-Rad). qPCR
was performed with 10 ng of cDNA preparation and the iTaq Universal SYBR
Green Supermix (Bio-Rad) in a CFX96 Real-Time machine (Bio-Rad). The
expression of PC in each sample was normalized against the expression of
Ubiquitin C used as housekeeping gene. The primer sequences and qPCR
conditions are available upon request. The expression of PC in cells transfected
with siRNA relative to the one in cells transfected with scrambled control was
calculated with the 2-DDCT method.
Immunoﬂuorescence. Cells plated on glass coverslips (Thermo scientiﬁc)
were washed in PBS and ﬁxed for 20min in ice-cold paraformaldehyde 4%
and permeabilized/blocked in 1% BSA, 0.1% Triton for 30min. Primary antibody
(anti-PCB antibody (3H2AD9; Abcam, ab110314), 1:100) was incubated overnight
at 4 C. Secondary antibodies (Alexa Fluor 488 Goat Anti-Mouse IgG (1/2,000,
Invitrogen) were incubated for 1 h, at room temperature in the dark. Slides were
mounted in Vectashield, containing DAPI and acquisitions were performed using
Axioimager Z1 Zeiss, with apotome system.
Cell proliferation. A total of 50,000 cells were plated on six-well plates, transfected
as described and passed before reaching conﬂuence into 10 cm dishes. Growth
curves were established by counting cells every 48 h after transfection for 8 days.
Experiments were performed three times, in duplicates.
Organic acid assays. Six snap-frozen tumour samples (1 SDHD, 2 SDHB, 2 NF1
and 1 MAX-mutated) and six imCC samples (3 WT and 3 KO) were processed by
organic extraction with ethylacetate, derivatization with N,O-bis(trimethylsilyl)
triﬂuoroacetamide with 1% trimethylchlorosilane, and analysed by gas
chromatography-tandem mass spectrometry on a GC–MS triple quadrupole
(Scion TQ, Bru¨ker Daltonics). Analytes were identiﬁed according to retention time
and mass spectrum in selected reaction monitoring mode based on standard
spectral reference libraries.
Immunohistochemistry. Six-micrometre sections were cut from 27 parafﬁn-
embedded tumour samples (Supplementary Table 2) and mounted on Superfrost
plus slides. The following antibodies and a standard procedure were used for
immunohistochemistry40 with Histogreen as a chromogen: anti-PC (1:100,
ab115579, abcam), anti-SCL25A13 (1:50, abcam). Antigen retrieval was performed
by boiling slides in Tris-EDTA buffer (pH9) for 45min for PC and in citrate buffer
(pH6) for SLC25A13. Images were acquired with a Leica DM400B microscope with
Leica Application Suite software version 2.8.1, and a Leica DFC420C camera
(Leica).
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